BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is...
2023-01-11 8:30 AM EST
BioMark Provides Business Update and Second Quarter Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") (an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the "Warrants") issued in relation to a private placement financing that closed on December 13, 2019 on a continuing effort to improve corporate value for its...
2022-11-28 8:30 AM EST
BioMark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle. The study published as part of the special issue of Cancers...
2022-10-27 8:30 AM EDT
The US Patent Office Grants BioMark Additional Patent for Its Liquid Biopsy Technology
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing and measuring treatment response for various forms of hard to detect and treat cancer. The technology can...
2022-09-20 8:30 AM EDT
BioMark to Present Validation Data of Its Multianalyte Metabolite Panel for Lung Cancer Screening at the ESMO Congress 2022
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it's abstract titled "Metabolomic Profiling for the Early Detection of Lung Cancer" has been accepted for presentation at the upcoming ESMO Congress 2022 taking place on September 9 – 13, 2022 in Paris, France. The Company will...
2022-09-08 8:30 AM EDT
BioMark Selected by the Medical Alley and Investissement Quebec to Join the Us Go-To-Market Accelerator
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") have been selected among the top 10 innovative companies to participate in the 2022 MedTech & Digital Health U.S. Market Access Program for...
2022-09-01 8:30 AM EDT
BioMark Provides First-Quarter 2022 Financial Results and Operational Update
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies announced today its financial results and operational update for the quarter ended June 30, 2022. "We closed out the quarter with great milestone accomplishment that reflect the ongoing momentum we have built towards our commercialization...
2022-08-30 8:30 AM EDT
BioMark Provides Financial Results for the Year Ended March 31, 2022, and Recent Corporate Highlights
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-year ended March 31, 2022 "We closed out the year with great milestone accomplishment that reflects the ongoing momentum we have built toward our...
2022-07-14 8:30 AM EDT
BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that it has been successful in obtaining a novel patent in Japan, No. 7038044, further strengthening the Company's intellectual property position worldwide and coverage of its...
2022-06-21 8:30 AM EDT
BioMark Diagnostics and the Icahn School of Medicine at Mount Sinai Announce Partnership to Advance Early Lung Cancer Screening Technology
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that BioMark and the Icahn School of Medicine at Mount Sinai in New York ("Icahn Mount Sinai") have entered into collaborative research agreement to work together on clinical studies related to early lung cancer diagnosis...
2022-06-07 8:30 AM EDT
BioMark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private placement for gross proceeds of $1,265,500 wherein BioMark issued...
2022-05-04 8:30 AM EDT
BioMark to Present New Cancer Screening Data Using the LDTD-MS/MS Technique at the Annual ASMS Conference on Mass Spectrometry
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 - 9, 2022 at the Minneapolis Convention Center in Minneapolis,...
2022-04-27 8:30 AM EDT
BioMark Provides the Third Quarter Operational Update and 2022 Outlook
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2021. "We closed out the quarter with great milestone accomplishment that reflect the ongoing momentum we have built toward our goal to improve early detection for lung cancer...
2022-03-01 8:30 AM EST
BioMark to Present at the Virtual Biotech Showcase and the Digital RESI JPM 2022 Conferences
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") was selected as one of the Innovator's Pitch Challenge participants at Digital RESI JPM 2022. Dr. Jean-François Haince, General Manager and Chief...
2022-01-10 8:30 AM EST
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be participating in a sponsored research project which aims to enhance the efficiency of current lung cancer screening programs and...
2021-11-30 8:30 AM EST
BioMark participera avec Astrazeneca, Pfizer Canada et la Fondation de l'IUCPQ à un projet de 3,5 m$ pour améliorer la détection précoce du cancer du poumon
Vancouver, British Columbia--(Newsfile Corp. - 30 novembre 2021) - BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que sa filiale québécoise en propriété exclusive Solutions de Diagnostic BioMark. («BDS») participera à un projet de recherche subventionnée qui vise à optimiser l'efficacité des programmes...
2021-11-30 8:30 AM EST
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, today reports its operational update for the second quarter ended September 30, 2021. The Company also announces it intends to extend the warrant exercise term on a continuing effort to improve corporate value for its shareholders. Highlights...
2021-11-25 8:30 AM EST
BioMark Secures Funding to Accelerate Development of Its Liquid Biopsy Assay in Quebec
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS")., is receiving advisory services and funding of up to CAD $169,550 from the National Research Council of Canada Industrial Research Assistance Program (NRC...
2021-11-16 8:30 AM EST
BioMark obtiens un financement pour accélérer le développement de sa technologie de biopsie liquide au Québec
Vancouver, British Columbia--(Newsfile Corp. - 16 novembre 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark»), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que sa filiale québécoise en propriété exclusive BioMark Diagnostic Solutions Inc. («BDS») recevra des services-conseils ainsi qu'un financement pouvant atteindre 169 550 $ CAD dans le...
2021-11-16 8:30 AM EST
BioMark Recognizes and Supports the Lung Cancer Awareness Month
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. There are fundamental strides being made in both the early diagnosis and more effective therapeutic intervention that will...
2021-11-10 8:30 AM EST